Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB drug performs well in mid-phase psoriasis trial
The EUA authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses
The EUA authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses
The study will investigate the safety, tolerability, pharmacokinetics and preliminary efficacy of INNO-406 in adult patients with Gleevec-resistant or intolerant Philadelphia positive (Ph+) leukemia or relapsed/refractory Ph+ acute
Gemzar, which is already approved in lung, pancreatic and breast cancer, generated sales of $1.3 billion last year, making it Lilly’s second best-selling drug. In the latest approval,
AFP-464 (aminoflavone pro-drug) is a novel anticancer agent currently being investigated in two phase I clinical trials sponsored by the National Cancer Institute (“NCI”) in patients with solid
The compound is currently being developed in phase I. The two companies plan to jointly develop and commercialize this novel compound for multiple autoimmune disorders. “Together, we are
BL-3020 is a peptide that reduces food intake by binding to specific receptors in the brain that control appetite. In contrast to most peptide-based drugs, it has been
In this blinded, randomized study, seven pigs received their own adipose stem and regenerative cells (treated) or a saline injection. Autologous adipose stem and regenerative cells were extracted
The cancer-research community has long recognized lysophosphatidic acid (LPA) as a significant contributor to cancer through its promotion of cancer-cell growth and metastasis in a broad range of
In the collaboration, researchers from the company and the University’s Southwestern Medical Center will evaluate the use of RNAi therapeutics directed to a disease target called proprotein convertase
Alnylam and Inex formed the collaboration in March 2006. The results to date encourage both parties to believe that Alnylam’s RNAi therapeutics can be efficiently encapsulated in Inex’s